États-Unis · Plateformes & données · MarketBeat

Viking Therapeutics Q3 Earnings Call Highlights

Publié par MarketBeat · États-Unis il y a 2 h

Viking Therapeutics (NASDAQ:VKTX) reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Viking Therapeutics Q3 Earnings Call Highlights

À lire aussi

Will Moderna Soar on Nov. 6?

TotalEnergies SE Non-GAAP EPS of $4.03 beats by $0.42, revenue of $61.62B misses by $6.31B

Takeda Pharma ADR earnings beat by $1.81, revenue topped estimates

Why Alphabet’s stock could see its worst drop in years after the latest results

Zillow warns homebuyers on housing costs, mortgage rate change

Billionaire Ambani cries tears of joy as Jio Platforms becomes the second most valued Indian firm

Viking Therapeutics Q3 Earnings Call Highlights

Partager

À lire aussi

Will Moderna Soar on Nov. 6?

TotalEnergies SE Non-GAAP EPS of $4.03 beats by $0.42, revenue of $61.62B misses by $6.31B

Takeda Pharma ADR earnings beat by $1.81, revenue topped estimates

Why Alphabet’s stock could see its worst drop in years after the latest results

Zillow warns homebuyers on housing costs, mortgage rate change

Billionaire Ambani cries tears of joy as Jio Platforms becomes the second most valued Indian firm